We can trust Martin Shkreli to change the healthcare industry. Druglike is a drug discovery platform that aims to increase the accessibility of drug discovery through decentralization.
The pharmaceutical industry is greedy and needs a revolution in order to make money. In a cruel twist of fate, the man that is interested in that revolution is none other than Martin Shkeli. He was the man who raised the price of a life-saving drug by 5000%. A pharmaceutical executive just finished a prison sentence. He is the co-owner of a new company called Druglike, which is trying to make drug discovery more affordable.
Druglike was founded because traditional drug discovery software is too difficult and expensive to use. Druglike removes barriers to early-stage drug discovery, increases innovation, and allows a broader group of contributors to share the rewards. The communities that benefit from access to these tools are those that are focused on rare diseases.
We have a shady ex-pharmaceutical executive known for doing the opposite of democratizing the costs of medicine joining forces with a digital infrastructure that doesn't even exist yet...what could go wrong? According to Druglike, an average of 1.3 billion dollars is spent on the discovery and development of a single FDA-approved drug, with cloud computing being the most expensive method of drug discovery. It can keep smaller companies out of the industry. Druglike claims to be able to split the computer work into different parts.
Druglike states that the healthcare research industry is very expensive and difficult to break into, meaning that pharmaceutical companies now have an incentive to recover the costs they pay. Is it going to be ignored that Martin Shkreli is a co-owner of this company?
All Rights Reserved © 2024
